EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial

Dapagliflozin nach transkatheter Aortenklappenimplantation nach Frailty in der DapaTAVI-Studie

Rafael Gonzalez-Manzanares iD, Soledad Ojeda iD, Ignacio Amat-Santos iD, Albert Ariza-Solé iD, Rafael Romaguera iD, Diego López Otero iD, Luis Nombela-Franco iD, Livia Gheorge iD, Jorge Sanz-Sánchez iD, Carlos Baladrón Zorita, Ignacio Gallo iD, Rafael Cobas Paz und 29 weitere

Journal of the American Heart Association · 20.10.2026 · 15 (20)

DOI: 10.1161/jaha.126.051379 ↗

Auf einen Blick

In einer Post-hoc-Analyse der DapaTAVI-Studie war Dapagliflozin nach TAVI bei frailen Patient:innen mit einem geringeren Risiko für Tod oder Verschlechterung der Herzinsuffizienz verbunden. Der Effekt hing von der Frailty ab.

Fragestellung

Unterscheidet sich der Nutzen von Dapagliflozin nach TAVI je nach Frailty-Status?

Methode

Post-hoc-Analyse der DapaTAVI-Studie; Frailty per FRAIL-Scale; primärer Endpunkt: Tod oder Verschlechterung der Herzinsuffizienz nach 1 Jahr.

Ergebnisse

1222 Patient:innen. 47,2 % frail, 40,3 % prefrail, 12,4 % robust. Primärer Endpunkt bei 215 (17,6 %) innerhalb von 12 Monaten. Dapagliflozin: HR 0,53 (95 %-KI 0,36–0,77) bei frailen, nicht bei prefrail oder robust.

Schlussfolgerung der Autor:innen

Frailty war häufig und unabhängig mit schlechteren Ergebnissen nach TAVI verbunden. Dapagliflozin schien bei Patient:innen mit Frailty einen größeren relativen Nutzen zu haben.

Kernaussagen

  • Frailty war mit schlechteren Ergebnissen nach TAVI verbunden
  • Dapagliflozin senkte den primären Endpunkt nur bei frailen Patient:innen
  • Kein Hinweis auf eine veränderte Sicherheit durch Frailty

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.10.2026. Verfasst von Rafael Gonzalez-Manzanares und 40 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology Reina Sofia University Hospital Córdoba Spain. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Benzhydryl Compounds, Frailty, Glucosides. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Frailty is common in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and portends worse outcomes. Whether the benefit of posttranscatheter aortic valve implantation dapagliflozin differs by frailty is uncertain.

Methods

In this post hoc analysis, we investigated the efficacy of dapagliflozin according to frailty status in the DapaTAVI (Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation) trial. Frailty was assessed through the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight scale (robust=0, prefrail=1–2, frail=3–5). The primary outcome was the composite of all‐cause death or worsening heart failure at 1 year.

Results

Among 1222 patients with baseline frailty assessment, 47.2% were frail, 40.3% prefrail, and 12.4% robust. Over 12 months, 215 patients (17.6%) experienced the primary end point. Patients who were prefrail and frail had higher risk than robust patients (adjusted hazard ratios [HRs], 1.88 [95% CI, 1.05–3.38] and 2.29 [1.29–4.07], respectively; P =0.004). Dapagliflozin was associated with a lower risk of the primary end point in patients who were frail (HR, 0.53 [95% CI, 0.36–0.77]) but not in those who were prefrail (HR, 1.01 [95% CI, 0.66–1.55]) or robust patients (HR, 1.26 [95% CI, 0.42–3.75]); P for interaction=0.021. There was no evidence that frailty modified the safety profile of dapagliflozin.

Conclusions

Frailty was common and independently associated with worse outcomes after transcatheter aortic valve implantation. Dapagliflozin appeared to confer greater relative benefit in patients with frailty.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve StenosisBenzhydryl CompoundsFrailtyGlucosidesSodium-Glucose Transporter 2 InhibitorsTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleFrail ElderlyHeart FailureRisk FactorsTime FactorsTreatment Outcome

Stichwörter der Autor:innen

SGLT2 inhibitorsTAVIaortic stenosisfrailtyheart failure

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Cardiology Reina Sofia University Hospital Córdoba Spain.
  • Maimonides Biomedical Research Institute of Cordoba (IMIBIC) Córdoba Spain.
  • Centro Nacional de Investigaciones Cardiovasculares Madrid Spain.
  • Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV) Madrid Spain.
  • Department of Medicine University of Córdoba Córdoba Spain.
  • Cardiology Department University Clinical Hospital of Valladolid Spain.

ORCID-Profile: Rafael Gonzalez-Manzanares, Soledad Ojeda, Ignacio Amat-Santos, Albert Ariza-Solé, Rafael Romaguera, Diego López Otero, Luis Nombela-Franco, Livia Gheorge, Jorge Sanz-Sánchez, Ignacio Gallo, Victoria Vilalta, Gabriela Veiga Fernández, Juan Gabriel Córdoba Soriano, Pedro Cepas-Gillén, Miriam Sandín Rollán, Ricardo Palma-Carbajal, Pablo Avanzas, Sergio García Blas, Javier Martín Moreiras, Nieves Gonzalo, German Calle, José Luis Díez, Sandra Santos-Martínez, Rocío González Ferreiro, Eduard Fernandez-Nofrerias, Gabriela Tirado, Inmaculada González Bermúdez, Xavier Rosselló, Borja Ibáñez, Sergio Raposeiras Roubín

Zitieren

APA

Gonzalez-Manzanares, R., Ojeda, S., Amat-Santos, I., Ariza-Solé, A., Romaguera, R., López Otero, D., Nombela-Franco, L., Gheorge, L., Sanz-Sánchez, J., Baladrón Zorita, C., Gallo, I., Cobas Paz, R., Muñoz García, A. J., Vilalta, V., Veiga Fernández, G., Córdoba Soriano, J. G., Cepas-Gillén, P., Sandín Rollán, M., Flores Ríos, X., …, & Raposeiras Roubín, S. (2026). Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial. Journal of the American Heart Association, 15(20). https://doi.org/10.1161/jaha.126.051379

Vancouver

Gonzalez-Manzanares R, Ojeda S, Amat-Santos I, Ariza-Solé A, Romaguera R, López Otero D, et al. Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial. Journal of the American Heart Association. 2026;15(20). doi:10.1161/jaha.126.051379

BibTeX
@article{GonzalezManzanares2026,
  author = {Gonzalez-Manzanares, Rafael and Ojeda, Soledad and Amat-Santos, Ignacio and Ariza-Solé, Albert and Romaguera, Rafael and López Otero, Diego and Nombela-Franco, Luis and Gheorge, Livia and Sanz-Sánchez, Jorge and Baladrón Zorita, Carlos and Gallo, Ignacio and Cobas Paz, Rafael and Muñoz García, Antonio Jesús and Vilalta, Victoria and Veiga Fernández, Gabriela and Córdoba Soriano, Juan Gabriel and Cepas-Gillén, Pedro and Sandín Rollán, Miriam and Flores Ríos, Xacobe and Palma-Carbajal, Ricardo and Martín Reyes, Roberto and Avanzas, Pablo and García Blas, Sergio and Franco-Peláez, Juan A and Martín Moreiras, Javier and Gonzalez Juanatey, José Ramón and Gonzalo, Nieves and Calle, German and Díez, José Luis and Santos-Martínez, Sandra and González Ferreiro, Rocío and Muñoz García, Erika and Fernandez-Nofrerias, Eduard and Sanmartín, Xoan and Tirado, Gabriela and Gutierrez Barri, Alejandro and González Bermúdez, Inmaculada and Rosselló, Xavier and Fuster, Valentín and Ibáñez, Borja and Raposeiras Roubín, Sergio},
  title = {Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {20},
  doi = {10.1161/jaha.126.051379}
}
Kostenlos starten →